RECOMMENDATIONS
Recommendation 1
2.21 The
committee recommends that the government examine ways in which there can be
greater engagement with consumers in decisions to create new therapeutic groups,
particularly when considering the potential impacts new therapeutic groups may
have on consumers.
Recommendation 2
2.42 The
committee recommends that the Pharmaceutical Benefits Advisory Committee:
- develop agreed principles of what
constitutes "interchangeable on an individual patient basis";
- develop criteria by which the
"interchangeability" of a medicine will be determined; and
- publish both the agreed principles and
criteria.
Recommendation 3
3.10 The
committee recommends that the Department of Health and Ageing provide regular
and ongoing education and information to prescribers to ensure they are aware
of the exemptions from payment of a brand premium and the process for seeking
those exemptions on behalf of a patient.
Recommendation 4
4.8 The
committee recommends that:
- the threshold for Cabinet consideration
of high cost medicines be adjusted, initially to the value the threshold would
have had, had it been indexed annually since 2001;
- subsequently, the threshold should be
indexed annually; and
- the Department of Health and Ageing
examine the most appropriate indicator for indexing the threshold.
Navigation: Previous Page | Contents | Next Page